Drugs / BNT314
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06150183 | Nov 2023 → Jun 2027 expected | cancer | BioNTech SE | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07079631 | Jul 2025 → Dec 2030 expected | colorectal cancer | BioNTech SE | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT314 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07079631 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT06150183 ↗ |